A recent study lead by researchers at Massachusetts General Hospital (MA, USA) has highlighted a novel mechanism behind resistance to angiogenesis inhibitors.
Browsing: Taxonomy > Biological and targeted therapies
Listen to our exclusive interview with Philip A Philip to find out about novel agents and strategies on the horizon for pancreatic cancer.
In this article, the authors provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data.
This prospective, noninterventional study evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab.
Listen to this exclusive interview with Dirk Arnold from Klinik für Tumorbiologie (Freiburg, Germany) about current treatment options for rectal cancer, how we can define a strategy for oligometastic rectal cancer and his hopes for the future of this field.
TET-activating strategies represent an exciting new avenue for cancer management, find out more in this editorial from Epigenomics.
In this research article from Immunotherapy find out about a somatic cell reprogramming procedure which may provide a novel and effective means to treat malignancies.
Researchers have uncovered a novel pathway involved in cancer-induced bone pain and subsequently a novel mechanism to inhibit the pain.
In this editorial from Future Oncology the different types of endometrial cancer are appraised.